Gibson J R
J Antimicrob Chemother. 1983 Mar;11(3):217-21. doi: 10.1093/jac/11.3.217.
Two-hundred and thirty patients with a diagnosis of presumptive bacterial conjunctivitis were assessed in a randomized double-blind multicentre trial. In two of the centres the patients had been treated with either trimethoprim-polymyxin B or neomycin-polymyxin B-gramicidin ophthalmic solution. In the other two centres the patients had been treated with either trimethoprim-polymyxin B or chloramphenicol ophthalmic solution. All of the preparations used were shown to be effective and very few adverse reactions were encountered. No significant difference in clinical efficacy could be demonstrated between trimethoprim-polymyxin B and neomycin-polymyxin B -gramicidin but trimethoprim-polymyxin B was found to be significantly better (P = 0.03) than chloramphenicol in reducing signs and symptoms.
在一项随机双盲多中心试验中,对230名诊断为疑似细菌性结膜炎的患者进行了评估。在其中两个中心,患者接受了甲氧苄啶-多粘菌素B或新霉素-多粘菌素B-短杆菌肽眼药水治疗。在另外两个中心,患者接受了甲氧苄啶-多粘菌素B或氯霉素眼药水治疗。所有使用的制剂均显示有效,且很少出现不良反应。在甲氧苄啶-多粘菌素B与新霉素-多粘菌素B-短杆菌肽之间未发现临床疗效有显著差异,但在减轻体征和症状方面,甲氧苄啶-多粘菌素B被发现显著优于氯霉素(P = 0.03)。